Aster DM Healthcare Ltd
Aster DM Healthcare Limited is one of the largest integrated private healthcare service providers operating in GCC (Gulf Cooperation Council) countries and an emerging player in India. With an inherent emphasis on clinical excellence, it is one of the few entities in the world with a strong presence across primary, secondary, tertiary and quaternary healthcare. [1]
- Market Cap ₹ 31,111 Cr.
- Current Price ₹ 601
- High / Low ₹ 675 / 386
- Stock P/E 96.4
- Book Value ₹ 59.4
- Dividend Yield 0.83 %
- ROCE 139 %
- ROE 200 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 149% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 73.5%
- Company has been maintaining a healthy dividend payout of 1,274%
- Company's median sales growth is 32.8% of last 10 years
Cons
- Stock is trading at 10.2 times its book value
- Promoter holding has decreased over last quarter: -1.51%
- Promoters have pledged or encumbered 40.7% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap Nifty Smallcap 100
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 53 | 189 | 380 | 530 | 595 | 760 | 747 | 1,116 | 1,534 | 2,036 | 2,320 | 2,368 | |
12 | 114 | 227 | 427 | 519 | 554 | 686 | 704 | 963 | 1,240 | 1,671 | 1,858 | 1,879 | |
Operating Profit | -11 | -60 | -38 | -47 | 12 | 41 | 74 | 42 | 153 | 293 | 366 | 463 | 489 |
OPM % | -1,256% | -114% | -20% | -12% | 2% | 7% | 10% | 6% | 14% | 19% | 18% | 20% | 21% |
86 | 40 | 51 | 390 | 14 | 83 | 113 | 21 | 82 | 50 | 48 | 6,061 | 104 | |
Interest | 3 | 34 | 135 | 228 | 54 | 11 | 33 | 36 | 47 | 56 | 83 | 91 | 86 |
Depreciation | 1 | 22 | 48 | 68 | 59 | 64 | 89 | 95 | 99 | 104 | 121 | 145 | 148 |
Profit before tax | 72 | -77 | -170 | 47 | -87 | 49 | 65 | -68 | 90 | 182 | 209 | 6,288 | 359 |
Tax % | 2% | 1% | 0% | 0% | 0% | 1% | 6% | 1% | -0% | 5% | 25% | 1% | |
70 | -78 | -170 | 47 | -87 | 48 | 61 | -69 | 90 | 173 | 157 | 6,209 | 281 | |
EPS in Rs | 1.86 | -2.00 | -4.21 | 1.16 | -1.73 | 0.95 | 1.21 | -1.38 | 1.81 | 3.47 | 3.14 | 124.30 | 5.58 |
Dividend Payout % | 89% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3,819% | 4% |
Compounded Sales Growth | |
---|---|
10 Years: | 46% |
5 Years: | 25% |
3 Years: | 28% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | 55% |
5 Years: | 149% |
3 Years: | 302% |
TTM: | -94% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 33% |
3 Years: | 41% |
1 Year: | 50% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 44% |
3 Years: | 74% |
Last Year: | 200% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 375 | 389 | 403 | 403 | 505 | 505 | 497 | 497 | 500 | 500 | 500 | 500 |
Reserves | 103 | 209 | 535 | 1,925 | 2,421 | 2,475 | 2,434 | 2,367 | 2,081 | 2,257 | 2,420 | 2,466 |
266 | 384 | 1,914 | 645 | 110 | 125 | 349 | 417 | 895 | 1,072 | 1,216 | 1,574 | |
24 | 124 | 168 | 251 | 257 | 271 | 273 | 307 | 286 | 274 | 402 | 425 | |
Total Liabilities | 768 | 1,105 | 3,021 | 3,224 | 3,293 | 3,376 | 3,552 | 3,589 | 3,762 | 4,102 | 4,538 | 4,965 |
37 | 469 | 547 | 714 | 772 | 753 | 1,016 | 1,009 | 1,013 | 1,008 | 1,333 | 1,760 | |
CWIP | 287 | 100 | 130 | 63 | 17 | 70 | 20 | 11 | 23 | 67 | 39 | 55 |
Investments | 266 | 317 | 2,037 | 2,137 | 2,086 | 2,095 | 2,150 | 2,151 | 2,166 | 2,141 | 2,176 | 1,009 |
178 | 219 | 307 | 309 | 417 | 458 | 366 | 418 | 560 | 886 | 990 | 2,140 | |
Total Assets | 768 | 1,105 | 3,021 | 3,224 | 3,293 | 3,376 | 3,552 | 3,589 | 3,762 | 4,102 | 4,538 | 4,965 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-51 | -3 | -51 | 98 | 42 | 78 | 246 | 413 | 367 | ||||
-251 | -18 | -36 | 40 | -38 | -49 | -332 | -342 | 6,023 | ||||
222 | 95 | 7 | -126 | -12 | -18 | 92 | -67 | -6,298 | ||||
Net Cash Flow | -80 | 74 | -80 | 12 | -9 | 11 | 6 | 3 | 92 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 742 | 41 | 28 | 24 | 21 | 22 | 21 | 21 | 20 | 26 | 23 | 22 |
Inventory Days | 171 | 100 | 66 | 42 | 38 | 49 | 38 | 32 | 38 | 39 | 33 | |
Days Payable | 288 | 150 | 102 | 57 | 64 | 240 | 270 | 173 | 228 | 200 | 198 | |
Cash Conversion Cycle | 742 | -75 | -22 | -13 | 6 | -4 | -170 | -210 | -122 | -163 | -139 | -143 |
Working Capital Days | -11,217 | -74 | -67 | -17 | -28 | 21 | -94 | -72 | -55 | -29 | -33 | -15 |
ROCE % | 12% | -5% | -4% | -4% | -1% | 2% | 3% | -1% | 4% | 7% | 7% | 139% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 4h
-
Intimation Regarding 100 Days Campaign - "SAKSHAM NIVESHAK"
2d - 100-day ‘Saksham Niveshak’ campaign (28 Jul–6 Nov 2025) urging KYC updates and claiming unclaimed dividends.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
22 Aug - Participation in Motilal Oswal Annual Global Investor Conference on 03.09.2025; one-on-one, Mumbai, 10:00-18:00 IST.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
22 Aug - Participation of management of the Company in the Investors' Conference scheduled on 2nd September 2025 at Mumbai
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13 Aug - For schedule of participation in the Investors meeting
Annual reports
Concalls
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Dec 2024Transcript PPT
-
Nov 2024TranscriptNotesPPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Dec 2023Transcript PPT
-
Nov 2023TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptPPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptPPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Dec 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019Transcript PPT
-
Sep 2019Transcript PPT
-
Aug 2019Transcript PPT
-
Jun 2019Transcript PPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019Transcript PPT
-
Nov 2018TranscriptNotesPPT
-
Sep 2018TranscriptPPT
-
Aug 2018Transcript PPT
-
Jun 2018Transcript PPT
Business Segments Q1 FY25
1) Hospitals and Clinics (94%): The company has a network of 19 hospitals (vs 14 hospitals in FY22) and 13 clinics. These hospitals are located in the Maharastra (1), Karnataka (4), Kerala (6), Andhra (6) & Telangana (1). [1]
This business has registered a 23% YoY revenue growth and EBITDA grew by 28% in FY24, on the backdrop of an increased bed capacity of 550 beds, and cost optimization measures. Material cost has declined from 25% in FY22 to 22% in FY24. [2] [3]